Literature DB >> 25546797

Europe immunoglobulin map.

A Šedivá1, H Chapel, A Gardulf.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25546797      PMCID： PMC4285526          DOI： 10.1111/cei.12546

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  3 in total

Review 1.  Subcutaneous immunoglobulin replacement therapy: the European experience.

Authors:  Helen Chapel; Ann Gardulf
Journal:  Curr Opin Allergy Clin Immunol       Date:  2013-12

2.  European consensus proposal for immunoglobulin therapies.

Authors:  W A Carrock Sewell; Jacqueline Kerr; Marie-Emmanuelle Behr-Gross; Hans-Hartmut Peter
Journal:  Eur J Immunol       Date:  2014-08       Impact factor: 5.532

3.  Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.

Authors:  Ann Gardulf; Uwe Nicolay; Dipl Math; Oscar Asensio; Ewa Bernatowska; Andreas Böck; Beatriz T Costa-Carvalho; Carl Granert; Stefan Haag; Dolores Hernández; Peter Kiessling; Jan Kus; Nuria Matamoros; Tim Niehues; Sigune Schmidt; Ilka Schulze; Michael Borte
Journal:  J Allergy Clin Immunol       Date:  2004-10       Impact factor: 10.793
  3 in total
  6 in total

Review 1.  Comprehensive activities to increase recognition of primary immunodeficiency and access to immunoglobulin replacement therapy in Poland.

Authors:  Małgorzata Pac; Ewa Bernatowska
Journal:  Eur J Pediatr       Date:  2016-06-29       Impact factor: 3.183

2.  Use of subcutaneous immunoglobulin in primary immune deficiencies.

Authors:  Elif Karakoç Aydıner; Ayça Kıykım; Safa Barış; Ahmet Özen; Işıl Barlan
Journal:  Turk Pediatri Ars       Date:  2016-03-01

3.  Evaluation of ColdZyme® Mouth Spray on prevention of upper respiratory tract infections in a boy with primary immunodeficiency: a case report.

Authors:  Mats Clarsund; Ulf Blom; Ann Gardulf
Journal:  J Med Case Rep       Date:  2016-10-31

4.  Home-Based Treatment with Immunoglobulins: an Evaluation from the Perspective of Patients and Healthcare Professionals.

Authors:  Chantal A Zuizewind; Paul van Kessel; Christine M Kramer; Mary M Muijs; Janneke C Zwiers; Mattanja Triemstra
Journal:  J Clin Immunol       Date:  2018-11-12       Impact factor: 8.317

5.  Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.

Authors:  Roger H Kobayashi; Sudhir Gupta; Isaac Melamed; J Fernando Mandujano; Ai Lan Kobayashi; Bruce Ritchie; Bob Geng; Thomas Prescott Atkinson; Syed Rehman; Eva Turpel-Kantor; Jiří Litzman
Journal:  Front Immunol       Date:  2019-02-04       Impact factor: 7.561

6.  Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.

Authors:  Il-Kang Na; Matthew Buckland; Carlo Agostini; John David M Edgar; Vanda Friman; Mauricette Michallet; Silvia Sánchez-Ramón; Carmen Scheibenbogen; Isabella Quinti
Journal:  Eur J Haematol       Date:  2019-03-24       Impact factor: 2.997
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.